PALI

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium

Palisade Bio to present FSCD data at NYAS, signaling PALI-2108 potential

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Palisade Bio announced that Dr. Mitchell Jones will present on fibrostenotic Crohn&#039;s disease (FSCD) and its locally bioactivated PDE4 inhibitor prodrug PALI-2108 at the NYAS symposium. The talk emphasizes unmet FSCD needs and the mechanistic rationale for targeted PDE4 inhibition, with Palisade signaling Phase 2 trials in UC and Crohn&#039;s disease. If preclinical signals translate, the event could provide a near-term sentiment lift, though data readouts remain the key long-term catalysts.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Palisade to present FSCD data at NYAS symposium. Focus on locally bioactivated PDE4 inhibitor prodrug.</li><li>FSCD has no approved therapies; PDE4 inhibition may modulate inflammatory and fibrotic pathways.</li><li>PALI-2108 is a once-daily PDE4 prodrug. Designed for ileum/colon bioactivation.</li><li>Phase 2 in UC and Crohn&#039;s disease is planned; no dates disclosed.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Palisade Bio, Inc. (PALI)</strong>: Presenting FSCD prodrug data at NYAS; near-term sentiment risk/reward tied to any favorable signals from the event.</li><li><strong>New York Academy of Sciences (NYAS)</strong>: Venue for the symposium; potential indirect impact via scientific validation but not a tradable security.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News. The article reports a scheduled scientific conference presentation and program updates, which typically influences sentiment and speculative positions rather than immediate fundamentals.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>NYAS presentation could spark short-term positive sentiment for PALI.</li><li>No new top-line data announced at the conference.</li><li>Advancement toward Phase 2 in UC and Crohn&#039;s disease noted.</li><li>Biotech small-caps remain sensitive to trial-readout timing.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>June 9, 2026: NYAS symposium in New York hosting the presentation.</li><li>PALI-2108 described as Palisade&#039;s locally bioactivated PDE4 inhibitor prodrug.</li><li>Palisade reported positive results in Phase 1a and two Phase 1b trials (UC and FSCD).</li><li>Company is advancing toward Phase 2 in UC and Crohn&#039;s disease.</li><li>Palisade Bio ticker: PALI (NASDAQ).</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term NYAS talk could modestly lift PALI shares if signals are favorable; Phase 2 data remains the longer-term catalyst.</p>
  </section>
</section>


<article>
  <h2>Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium</h2>

  <section>
    <p><strong>Denver, CO, June  09, 2026  (GLOBE NEWSWIRE) -- </strong>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PALI">PALI</a>) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced Mitchell Jones, MD, PhD, President and Chief Medical Officer, will present at the New York Academy of Sciences ("NYAS") symposium, Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis, taking place on June 9, 2026, in New York, NY.</p>
  </section>

  <section>
    <h3>Event Overview and Focus</h3>
    <p>The symposium brings together leading experts from academia, industry and clinical research to explore advances in fibrosis biology, emerging multiomic insights and the development of novel therapeutic approaches across a range of fibrotic diseases.</p>
  </section>

  <section>
    <h3>Presentation Details and Therapeutic Focus</h3>
    <p>Dr. Jones' presentation, titled "Locally Bioactivated PDE4 Inhibitor Prodrug for the Treatment of Fibrostenotic Crohn's Disease (FSCD)," will discuss the significant unmet need associated with FSCD, the biological mechanisms underlying intestinal fibrosis and the potential role of locally bioactivated PDE4 inhibition as a novel therapeutic approach.</p>

    <p>"Fibrosis remains one of the most significant challenges facing patients with Crohn's disease, yet there are currently no approved therapies specifically designed to address FSCD," said Mitchell Jones, MD, PhD, President and Chief Medical Officer of Palisade Bio. "We are honored to participate in this important scientific meeting and look forward to contributing to the broader discussion surrounding fibrosis biology and emerging therapeutic strategies."</p>

    <p>The presentation will also highlight the scientific rationale supporting <strong>PALI-2108</strong>, Palisade's locally bioactivated PDE4 inhibitor prodrug. In addition, Dr. Jones will discuss preclinical findings supporting PDE4 inhibition as a potential strategy for modulating key inflammatory and fibrotic pathways implicated in FSCD.</p>
  </section>

  <section>
    <h3>About Palisade Bio and PALI-2108</h3>
    <p><strong>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PALI">PALI</a>)</strong> is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.</p>

    <p>The Company's lead program, <strong>PALI-2108</strong>, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and FSCD.</p>

    <p>Palisade is now advancing towards Phase 2 clinical studies in UC and Crohn's disease. For more information, please go to <a href="https://www.globenewswire.com/Tracker?data=HugM1QCQmFdpUxzT9v3a7yO5cWprF0X9MGElK260W24pCEWCHf_wB18PtdnhTgBHO7HK73BYgPIl8yKHvH2rHpyZ3mweFpI-xtfpporU0oI=" rel="nofollow" target="_blank">www.palisadebio.com</a>.</p>
  </section>

  <section>
    <h3>Forward-Looking Statements</h3>
    <p><strong>Forward Looking Statements</strong></p>
    <p>Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: the potential mechanisms of action and therapeutic benefits of PALI-2108 for the treatment of FSCD and UC and plans for and timing of regulatory submissions and approvals, clinical trials and efficacy readouts. These forward-looking statements are based on the Company's current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company's clinical trials; the Company's reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company's product candidates in clinical trials focused on the same or different indications; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.</p>
  </section>

  <section>
    <h3>Investor Relations Contact</h3>
    <p>JTC Team, LLC<br>Jenene Thomas<br>908-824-0775<br><a href="https://www.globenewswire.com/Tracker?data=s0tm1ECLq6P1yaR-aK5XxgEES56YyT7Uqa_VloT7kgLD3TFdZRkOqHx-YUCkRfzl36Tlxogum7uDGbgeeUTzag==" rel="nofollow" target="_blank">PALI@jtcir.com</a></p>
  </section>
</article>

Palisade Bio announced that Dr. Mitchell Jones will present on fibrostenotic Crohn's disease (FSCD) and its locally bioactivated PDE4 inhibitor prodrug PALI-2108 at the NYAS symposium. The talk emphasizes unmet FSCD needs and the mechanistic rationale for targeted PDE4 inhibition, with Palisade signaling Phase 2 trials in UC and Crohn's disease. If preclinical signals translate, the event could provide a near-term sentiment lift, though data readouts remain the key long-term catalysts.

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News